{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:19Z","timestamp":1793316259765,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":942,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"MacroGenics, Inc."},{"name":"Green Cross Corp"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1093\/annonc\/mdx002","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T01:41:19Z","timestamp":1485308479000},"page":"855-861","source":"Crossref","is-referenced-by-count":201,"title":["First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors"],"prefix":"10.1016","volume":"28","author":[{"given":"Y.J.","family":"Bang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Nordstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.R.","family":"Chichili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Lechleider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx002_bb0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx002_bb0015","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx002_bb0020","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx002_bb0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"37","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1093\/annonc\/mdx002_bb0030","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","article-title":"The immune system and response to HER2-targeted treatment in breast cancer","volume":"15","author":"Bianchini","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx002_bb0035","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1182\/blood.V94.12.4220.424k08_4220_4232","article-title":"Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fc gamma receptor polymorphisms in control and disease populations","volume":"94","author":"Lehrnbecher","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx002_bb0040","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx002_bb0045","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2007.15.7404","article-title":"The \u201cother\u201d signaling of trastuzumab: antibodies are immunocompetent drugs","volume":"26","author":"Gianni","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx002_bb0050","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/bcr3069","article-title":"Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc\u03b3 receptor binding properties","volume":"13","author":"Nordstrom","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdx002_bb0055","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1535-7163.1585.3.12","article-title":"Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer","volume":"3","author":"Tanner","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdx002_bb0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-005-1026-z","article-title":"Population pharmacokinetics of trastuzumab in patient with HER2+ metastatic breast cancer","volume":"56","author":"Bruno","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx002_bb0065","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2005.03.184","article-title":"Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer","volume":"23","author":"Agus","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx002_bb0070","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2003.12.109","article-title":"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel","volume":"21","author":"Leyland-Jones","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx002_bb0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1093\/annonc\/mdx002_bb0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/annonc\/mdx002_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4331\/wjbc.v3.i4.73","article-title":"Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges","volume":"3","author":"Vugmeyster","year":"2012","journal-title":"World J Biol Chem"},{"key":"10.1093\/annonc\/mdx002_bb0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant anti-p185HER monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx002_bb0095","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx002_bb0100","first-page":"19a","article-title":"Efficacy and safety of 3-weekly herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study","volume":"21","author":"Carbonell Castellon","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.1093\/annonc\/mdx002_bb0105","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0960-9776(03)80128-5","article-title":"Pharmacokinetics of Herceptin administered three-weekly compared to weekly: a simulation based on data from the clinical studies","volume":"12","author":"Ghahramani","year":"2003","journal-title":"Breast"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/4\/855\/11121411\/mdx002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T18:23:02Z","timestamp":1658514182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419320678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0923753419320678"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}